Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study

INTRODUCTION: High-risk non-muscle invasive bladder cancer (HRNMIBC) is a heterogeneous disease that can be difficult to predict. While around 25% of cancers progress to invasion and metastases, the remaining majority of tumours remain within the bladder. It is uncertain whether patients with HRNMIB...

Descripción completa

Detalles Bibliográficos
Autores principales: Oughton, Jamie B, Poad, Heather, Twiddy, Maureen, Collinson, Michelle, Hiley, Victoria, Gordon, Kathryn, Johnson, Mark, Jain, Sunjay, Noon, Aidan P, Chahal, Rohit, Simms, Matt, Dooldeniya, Mohantha, Koenig, Phillip, Goodwin, Louise, Brown, Julia M, Catto, James W F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724134/
https://www.ncbi.nlm.nih.gov/pubmed/28801444
http://dx.doi.org/10.1136/bmjopen-2017-017913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724134/
https://www.ncbi.nlm.nih.gov/pubmed/28801444
http://dx.doi.org/10.1136/bmjopen-2017-017913

Ejemplares similares